Systems and methods for optimizing insulin dosage

Patent metadata

Field	Value
Publication number	US-9918635-B2
Application number	US-81831010-A
Country	US
Kind code	B2
Filing date	Jun 18, 2010
Priority date	Dec 23, 2008
Publication date	Mar 20, 2018
Grant date	Mar 20, 2018

Abstract

Embodiments of a testing method suitable for diabetic persons to optimize their administered insulin dosage comprise collecting one or more sampling sets of biomarker data, wherein each sampling set comprises a sufficient plurality of non-adverse sampling instances and wherein each sampling instance comprises an acceptable biomarker reading at a single point in time recorded upon compliance with adherence criteria, determining a biomarker sampling parameter from each sampling set, comparing the biomarker sampling parameter to a target biomarker range, calculating an insulin adjustment parameter associated with the biomarker sampling parameter if the biomarker sampling parameter falls outside the target biomarker range, adjusting the insulin dosage by the insulin adjustment parameter if the biomarker sampling parameter falls outside the target biomarker range and if the insulin dosage does not exceed maximum dosage, and exiting the testing method if the adjusted insulin dosage is optimized. The insulin dosage is optimized when one or more biomarker sampling parameters fall within a target biomarker range.

First claim

What is claimed is:

1. A testing method suitable for a diabetic person to optimize an administered insulin dosage comprising:
providing a structured collection procedure from a server of a health care provider to a collection device configured to guide the diabetic person through the structured collection procedure and optimize the administered insulin dosage, wherein the collection device comprises a meter configured to measure one or more selected biomarkers, a processor disposed inside the meter and coupled to a memory, wherein the memory stores the structured collection procedure provided from the server, and software having instructions that when executed by the processor causes the processor to instruct the diabetic person to collect one or more sampling sets of biomarker data in accordance with the structured collection procedure, wherein the server is a central repository for a plurality of the structured collection procedures;
executing the software on the collection device and according to instructions and timing provided by the structured collection procedure:
collecting one or more sampling sets of biomarker data, wherein each of the one or more sampling sets comprises a plurality of sampling instances recorded over a collection period and each sampling instance of the plurality of sampling instances comprises an acceptable biomarker reading recorded upon compliance with one or more acceptance criterion that is applied to the one or more sampling sets of biomarker data, wherein the one or more acceptance criterion comprises one or more considerations selected from the group consisting of: a patient diet, fasting or eating regimen; a patient exercise regimen; a patient lifestyle; a patient sleep regimen; insulin dosage amounts; and timing of biomarker reading collection;
wherein after each collection of the one or more sampling sets of biomarker data, said processor performs the processes of:
determining a biomarker sampling parameter from the one or more sampling sets of biomarker data whereby only these biomarker data are considered which are in compliance with the one or more acceptance criterion;
comparing the biomarker sampling parameter to a target biomarker range;
calculating an insulin adjustment parameter associated with the biomarker sampling parameter in response to the biomarker sampling parameter falling outside the target biomarker range;
adjusting an insulin dosage by an amount of the insulin adjustment parameter in response to the biomarker sampling parameter falling outside the target biomarker range and in response to the insulin dosage not exceeding maximum dosage;
exiting the testing method in response to the adjusted insulin dosage being optimized as an optimized insulin dosage such that the optimized insulin dosage is administered as the administered insulin dosage, otherwise repeating with a next sampling set of the one or more sampling sets of biomarker data, the optimized insulin dosage being achieved when the one or more biomarker sampling parameters fall within the target biomarker range; and
wherein the one or more acceptance criterion comprises an adherence criteria, and in response to the diabetic person failing to meet the adherence criteria, the processor tags the failing as an adherence event and informs the diabetic person via a display, then continues the testing method, wherein in response to a determination that a number of the adherence events in a sample period are obtained or a total number of the adherence events are reached in the testing method, the testing method is terminated;
categorizing, via the processor, the adherence events into tiers of either a lower weighted adherence event in response to a determination that the adherence event will not cause an error in at least one acceptable biomarker reading, or a higher weighted adherence event in response to a determination that the adherence event will cause the error in the at least one acceptable biomarker reading, wherein the lower weighted adherence event is an event that is not weighted as heavily as the higher weighted adherence event that affects the one or more sampling sets of biomarker data;
maintaining, by the health care provider, an electronic medical record for the diabetic person on the server; and
generating a hardcopy report of results of the collection procedure for the diabetic person via a computer of the health care provider.

2. The testing method of claim 1 wherein the insulin dosage is optimized when at least two consecutive biomarker sampling parameters fall within the target biomarker range.

3. The testing method of claim 1 further comprising conducting a new testing method after achieving the optimized insulin dosage.

4. The testing method of claim 1 wherein the collection period for the one or more sampling sets of biomarker data is defined as multiple sampling instances within a day, multiple sampling instances within a week, multiple sampling instances within consecutive weeks, or multiple sampling instances on consecutive days within a week.

5. The testing method of claim 1 wherein each sampling instance of the plurality of sampling instances comprises the acceptable biomarker reading and other contextual data associated with the acceptable biomarker reading, wherein the contextual data is selected from the group consisting of a time of collection, a date of collection, a time when the last meal was consumed, and combinations thereof.

6. The testing method of claim 1 further comprising collecting one or more additional sampling sets of biomarker data when the biomarker sampling parameter falls outside of the target biomarker range.

7. The testing method of claim 1 further comprising informing the health care provider of any biomarker readings indicative of an adverse event.

8. The testing method of claim 7 further comprising reducing the administered insulin dosage for any biomarker readings indicative of an adverse event.

9. The testing method of claim 7 wherein the adverse event is a hypoglycemic event.

10. The testing method of claim 1 wherein a biomarker reading below a lower threshold is indicative of an adverse event.

11. The testing method of claim 1 further comprising contacting the health care provider for any biomarker readings indicative of an adverse event.

12. The testing method of claim 1 wherein the administered insulin dosage is decreased for any biomarker readings indicative of an adverse event.

13. The testing method of claim 1 further comprising meeting entry criteria required for beginning to collect the one or more sampling sets of biomarker data.

14. The testing method of claim 1 wherein the one or more acceptance criterion requires that a prescribed dosage be administered throughout the collection period.

15. The testing method of claim 1 wherein the one or more acceptance criterion requires a fasting period before collection of the one or more sampling sets of biomarker data.

16. The testing method of claim 13 wherein the entry criteria requires that the diabetic person be afflicted with type 2 diabetes.

17. The testing method of claim 13 wherein the entry criteria requires that the diabetic person be limited to oral diabetes medication prior to conducting the testing method.

18. The testing method of claim 1 wherein the maximum insulin dosage is set by the health care provider.

19. The testing method of claim 1 wherein the biomarker sampling parameter is determined by averaging sampling instances, summing the sampling instances, performing a graphical analysis

Assignees

• Bousamra Steven
• Weinert Stefan
• Rasch Menges Juergen
• Walling P Douglas
• Price John F
• Eikmeier Heino
• Kraeling Birgit
• Werner Karl
• Porsch Ulrich
• Roche Diabetes Care Inc

Inventors

• Bousamra Steven
• Weinert Stefan
• Rasch-Menges Juergen
• Walling P Douglas
• Price John F
• Eikmeier Heino
• Kraeling Birgit
• Werner Karl
• Porsch Ulrich

Classifications

• G16H20/17

  delivered via infusion or injection · CPC title

• G16H40/63

  for local operation · CPC title

• G16H20/10

  relating to drugs or medications, e.g. for ensuring correct administration to patients · CPC title

• A61B5/05

  Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fields; Measuring using microwaves or radio waves (measuring movement of the entire body or parts thereof A61B5/11; detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof A61B5/24) · CPC title

• G16H10/20

  for electronic clinical trials or questionnaires · CPC title